Loading...

CMS Reform And Capacity Expansion Will Unlock Long Term Value

Published
25 Apr 25
Updated
20 Nov 25
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
27.4%
7D
-17.6%

Author's Valuation

US$7.531.7% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on 20 Nov 25

Fair value Decreased 6.25%

ORGO: Anticipated 2025 Guidance And Promising Data Will Support Share Price Expansion

Analysts have revised their price target for Organogenesis Holdings downward from $8.00 to $7.50. This reflects a tempered outlook based on updated forecasts for revenue growth and profit margins.

Shared on 15 Aug 25

With no change in key metrics such as Future P/E and Net Profit Margin, the consensus analyst price target for Organogenesis Holdings remains steady at $8.00. What's in the News Organogenesis updated full-year 2025 guidance: expects net product revenue between $480 million and $510 million (roughly flat to 6% growth) and net income (loss) ranging from a $6.4 million loss to a $16.4 million profit.

Shared on 01 May 25

Fair value Increased 14%